Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges.

Area of Science:

• Oncology
• Immunology
• Medical Research

Background:

• Immunotherapy, specifically anti-programmed cell death ligand-1 (PD-L1) immune checkpoint inhibitors, is approved for a subset of advanced triple-negative breast cancer (TNBC) patients.
• The combination of atezolizumab and nab-paclitaxel is a standard first-line therapy for metastatic TNBC with PD-L1-positive immune infiltrate.

Purpose of the Study:

• To review current knowledge on immune checkpoint inhibitors in clinical practice for breast cancer.
• To explore strategies for expanding immunotherapy indications in TNBC.
• To identify patient characteristics, immune markers, and combination therapies that predict or enhance treatment benefit.

Main Methods:

• Review of clinical trial data, including IMpassion130 and KEYNOTE-522.
• Analysis of current research on immune checkpoint inhibitors in breast cancer.
• Discussion of predictive markers and novel therapeutic strategies.

Main Results:

• Current immunotherapy approvals are limited to specific patient subsets in advanced TNBC.
• Ongoing research focuses on expanding immunotherapy use in both early and metastatic TNBC settings.
• Several markers are being evaluated to predict immunotherapy response.

Conclusions:

• There is a significant need to identify patient characteristics and biomarkers to broaden immunotherapy benefits in TNBC.
• Investigating immunotherapy in the early disease setting, alongside combination and sequencing strategies, is crucial.
• New approaches are being developed to enhance immune response and increase the number of patients benefiting from immunotherapy.